GENB Stock Analysis: Generate Biomedicines | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.593m USD | 12M Return: 19.1% | US3709201004 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 10.6M
Warnings
Tailwinds
Seasonality 0.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Generate Biomedicines, Inc. (NASDAQ: GENB) is a biotechnology company that applies generative biology and machine learning to design and develop novel protein-based therapeutics. The company is working to program proteins computationally as a way to bypass the trial-and-error limitations of conventional drug discovery.
Its disclosed pipeline includes GB-0895, an investigational long-acting anti-TSLP monoclonal antibody being developed for severe asthma with a target dosing interval of every six months; GB-4362, a monoclonal antibody targeting an MMAE payload; and GB-5267, a MUC16-directed CAR-T cell therapy. The company also operates the Generate Platform, which it describes as a therapeutic-area- and protein-modality-agnostic system intended to integrate computational design with scalable laboratory infrastructure.
The company was originally incorporated as Generate Biologics, Inc. in 2018, was renamed Generate Biomedicines, Inc. in February 2020, and is headquartered in Somerville, Massachusetts, in the Greater Boston biotechnology cluster. Like many computational biology peers, its business model centers on applying AI/ML-derived protein designs across multiple therapeutic modalities, rather than focusing on a single disease area or drug class.
- GB-0895 Phase 2 data readout in severe asthma
- Preclinical milestones advance GB-4362 and GB-5267 programs
- Platform partnerships and capital allocation post-IPO
- Competition from AI-driven biotech drug discovery rivals
| Net Income: -222.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.44 > 0.02 and ΔFCF/TA -20.39 > 1.0 |
| NWC/Revenue: 1.27k% < 20% (prev 1.57k%; Δ -295.1% < -1%) |
| CFO/TA -0.43 > 3% & CFO -240.3m > Net Income -222.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.30 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (50.1m) vs prev -60.70% < -2% |
| Gross Margin: 89.92% > 18% (prev 100.0%; Δ -10.08% > 0.5%) |
| Asset Turnover: 6.02% > 50% (prev 3.95%; Δ 2.07% > 0%) |
| Interest Coverage Ratio: -228.7 > 6 (EBIT TTM -231.4m / Interest Expense TTM 1.01m) |
| A: 0.74 (Total Current Assets 470.3m - Total Current Liabilities 56.6m) / Total Assets 561.7m |
| B: -1.43 (Retained Earnings -805.0m / Total Assets 561.7m) |
| C: -0.43 (EBIT TTM -231.4m / Avg Total Assets 540.0m) |
| D: 4.32 (Book Value of Equity 456.0m / Total Liabilities 105.6m) |
| Altman-Z'' = 1.81 = BBB |
As of October 29, 2026, the stock is trading at USD 15.38 with a total of 3,914,564 shares traded. Over the past week, the price has changed by +17.32%, over one month by +3.15%, over three months by +17.05% and over the past year by +19.13%.
Current recommended Stop Loss: 13.90 (which is 9.6% or 1.7 ATR below the current price).
Generate Biomedicines has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy GENB.
- StrongBuy: 4
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 27 | 75.6% |
P/S = 60.1463
P/B = 3.4912
Revenue TTM = 32.5m USD
EBIT TTM = -231.4m USD
EBITDA TTM = -218.2m USD
Long Term Debt = 49.0m USD (estimated: total debt 62.6m - short term 13.6m)
Short Term Debt = 13.6m USD (from shortTermDebt, last quarter)
Debt = 62.6m USD (from shortLongTermDebtTotal, last quarter) (leases 62.6m already included)
Net Debt = -394.8m USD (calculated: Debt 62.6m - CCE 457.4m)
Enterprise Value = 1.20b USD (1.59b + Debt 62.6m - CCE 457.4m)
Interest Coverage Ratio = -228.7 (Ebit TTM -231.4m / Interest Expense TTM 1.01m)
EV/FCF = -4.87x (Enterprise Value 1.20b / FCF TTM -245.9m)
FCF Yield = -20.52% (FCF TTM -245.9m / Enterprise Value 1.20b)
FCF Margin = -756.9% (FCF TTM -245.9m / Revenue TTM 32.5m)
Net Margin = -685.9% (Net Income TTM -222.8m / Revenue TTM 32.5m)
Gross Margin = 89.92% ((Revenue TTM 32.5m - Cost of Revenue TTM 3.27m) / Revenue TTM)
Gross Margin QoQ = none% (prev 54.69%)
Tobins Q-Ratio = 2.13 (Enterprise Value 1.20b / Total Assets 561.7m)
Interest Expense / Debt = 1.62% (Interest Expense 1.01m / Debt 62.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -182.8m (EBIT -231.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.30 (Total Current Assets 470.3m / Total Current Liabilities 56.6m)
Debt / Equity = 0.14 (Debt 62.6m / totalStockholderEquity, last quarter 456.0m)
Debt / EBITDA = 1.81 (negative EBITDA) (Net Debt -394.8m / EBITDA -218.2m)
Debt / FCF = 1.61 (negative FCF - burning cash) (Net Debt -394.8m / FCF TTM -245.9m)
Total Stockholder Equity = -616.0m (last fiscal year from totalStockholderEquity)
RoA = -41.26% (Net Income -222.8m / Total Assets 561.7m)
RoE = 36.17% (negative equity) (Net Income TTM -222.8m / Total Stockholder Equity -616.0m)
RoCE = 40.82% (negative capital employed) (EBIT -231.4m / Capital Employed (Equity -616.0m + L.T.Debt 49.0m))
RoIC = -35.36% (negative operating profit) (NOPAT -182.8m / Invested Capital 517.0m)
WACC = 8.82% (E(1.59b)/V(1.66b) * Re(9.12%) + D(62.6m)/V(1.66b) * Rd(1.62%) * (1-Tc(0.21)))
Discount Rate = 9.12% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 89.48 | Cagr: 35.15%
[DCF] Fair Price = unknown (Cash Flow -245.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.55 | Chg30d=+0.00% | Revisions=-17% | Analysts=4
EPS current Year (2026-12-31): EPS=-2.30 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+0.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.28 | Chg30d=+0.00% | Revisions=-40% | GrowthEPS=+0.9% | GrowthRev=-19.7%
[Analyst] Revisions Ratio: -25% (up=3, down=6)